Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-03-19
1999-06-08
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530307, A61K 3104
Patent
active
059104821
ABSTRACT:
The present invention provides a method for counteracting preeclampsia, eclampsia of pregnancy and preterm labor in a pregnant female mammal treated by administering thereto calcitonin gene-related peptide (CGRP) or its analogues including CGRP/adrenomedullin or their peptide or receptor-based analogues, or in combination with a progestin, and with or without a nitric oxide substrate, or a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI.sub.2 -mimetic, a thromboxane (TXA.sub.2) inhibitor, a compound possessing TXA.sub.2 -agonistic, and TXA.sub.2 -inhibiting properties, a compound possessing TXA.sub.2 -antagonistic and PGI.sub.2 -mimetic activities, and a TXA.sub.2 antagonist. CGRP, progesterone and some of the nitric oxide substrate and donor compounds are naturally occurring compounds. As such these agents do not have the same toxicity and allergy problems as the foreign substances that are currently used for similar purposes. During pregnancy uterine blood vessels and the uterine muscles are particularly sensitive to CGRP as well as nitric oxide. Therefore, one could administer a very small quantities of these drugs (i.e., intravenously, subcutaneous, or Implants), the effects are then seen mainly in the uterine muscle and blood vessels, namely increase the blood supply to the uteroplacental unit (hence nutrients and oxygen supply to the fetus through the improved placental circulation), and uterine muscular relaxation thereby ameliorate the signs and symptoms of preeclampsia, and eclampsia, and prevent preterm labor. At these dosages, virtually no systemic effects are induced, making CGRP (which is an endogenous natural product present in human body) extremely safe and effective.
REFERENCES:
patent: 4393226 (1983-07-01), Witiak et al.
patent: 5364841 (1994-11-01), Cooper et al.
patent: 5508045 (1996-04-01), Harrison et al.
patent: 5595970 (1997-01-01), Garfield et al.
patent: 5612314 (1997-03-01), Stamler et al.
patent: 5622973 (1997-04-01), Morriello et al.
Shew et al., Biosis AN 93:87984, 1993.
Fiscus, Caplus AN 1994:183589.
Tan, Medline AN 95136728, Oct. 1994.
Pennefather, Caplus AN 1990:605182.
Shew et al. "Role of Nitric Oxide in CGRP Relaxation" Peptides, v. 14, pp. 637-641, 1993.
International Search Report dated Jul. 30, 1997 (UTFG:216P).
Supowit et al., "Calcitonin Gene-Related Peptide is a Depressor in L-Name--Induced Preeclampsia," 50th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Chicago, Illinois, Sep. 17-20, 1996.
Yallampalli et al., "Calcitonin Gene related Peptide Reverses Hypertension and Decreases the Fetal Mortality Associated with L-Name-Infusion in Pregnant Rats," Society for Gynecological Investigation, Abstract No. 504, Philadelphia, Mar. 20-23, 1996.
Yallampalli et al., "Calcitonin Gene-Related Peptide Reverses the Hypertension and Significantly Decreases the Fetal Mortality in Pre-Eclampsia Rats Induced by N.sup.G -Nitro-L-Arginine Methyl Ester," Human Reproduction, 11(4):895-899, 1996.
Wimalawansa Sunil J.
Yallampalli Chandrasekhar
Board of Regents , The University of Texas System
Delaney Patrick R.
Tsang Cecilia J.
LandOfFree
Treatment or prevention of preeclampsia, eclampsia with calciton does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment or prevention of preeclampsia, eclampsia with calciton, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment or prevention of preeclampsia, eclampsia with calciton will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1683330